---
schema_version: "secwatch.filing_event.v1"
accession: "0001802768-26-000014"
form_type: "8-K"
ticker: "RPRX"
cik: "0001802768"
company_name: "Royalty Pharma plc"
filed_at: "2026-08-05T11:33:09+00:00"
generated_at: "2026-08-05T11:35:10.479520+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Royalty Pharma Q2 Royalty Receipts up 14% to $768M; raises FY 2026 guidance

## Summary
- Q2 Royalty Receipts $768M (+14% YoY); Portfolio Receipts $773M (+6%).
- Raised FY 2026 Portfolio Receipts guidance to $3.4B-$3.5B (from $3.325B-$3.45B).
- Acquired royalty on AstraZeneca's cliramitug for up to $425M ($125M upfront) in July.
- Capital Deployment YTD $1.1B; announced transactions value $1.7B.
- Paid Q2 dividend $0.235/share; repurchased $45M in shares.

## SEC filing metadata
- accession: 0001802768-26-000014
- form_type: 8-K
- ticker: RPRX
- cik: 0001802768
- company_name: Royalty Pharma plc
- filed_at: 2026-08-05T11:33:09+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802768/000180276826000014/0001802768-26-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802768/000180276826000014/rprx-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001802768-26-000014
- JSON: https://secwatch.observer/filing/0001802768-26-000014.json
- Plain text: https://secwatch.observer/filing/0001802768-26-000014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.